Publications
Detailed Information
Different degree of cytokinemia and T-cell activation according to serum IL-6 levels in critical COVID-19
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Chan Mi | - |
dc.contributor.author | Kim, Minji | - |
dc.contributor.author | Kang, Chang Kyung | - |
dc.contributor.author | Choe, Pyoeng Gyun | - |
dc.contributor.author | Kim, Nam Joong | - |
dc.contributor.author | Bang, Hyeeun | - |
dc.contributor.author | Cho, Taeeun | - |
dc.contributor.author | Shin, Hyun Mu | - |
dc.contributor.author | Kim, Hang-Rae | - |
dc.contributor.author | Park, Wan Beom | - |
dc.contributor.author | Oh, Myoung-don | - |
dc.date.accessioned | 2024-04-26T00:57:07Z | - |
dc.date.available | 2024-04-26T00:57:07Z | - |
dc.date.created | 2023-05-12 | - |
dc.date.created | 2023-05-12 | - |
dc.date.created | 2023-05-12 | - |
dc.date.created | 2023-05-12 | - |
dc.date.issued | 2023-04 | - |
dc.identifier.citation | Frontiers in Immunology, Vol.14 | - |
dc.identifier.issn | 1664-3224 | - |
dc.identifier.uri | https://hdl.handle.net/10371/199565 | - |
dc.description.abstract | IntroductionTocilizumab, a humanized anti-interleukin-6 receptor (IL-6R) antibody, is recommended for the treatment of severe to critical coronavirus diseases 2019 (COVID-19). However, there were conflicting results on the efficacy of tocilizumab. Therefore, we hypothesized that the differences in tocilizumab efficacy may stem from the different immune responses of critical COVID-19 patients. In this study, we described two groups of immunologically distinct COVID-19 patients, based on their IL-6 response. MethodsWe prospectively enrolled critical COVID-19 patients, requiring oxygen support with a high flow nasal cannula or a mechanical ventilator, and analyzed their serial samples. An enzyme-linked immunosorbent assay and flow cytometry were used to evaluate the cytokine kinetics and cellular immune responses, respectively. ResultsA total of nine patients with critical COVID-19 were included. The high (n = 5) and low IL-6 (n = 4) groups were distinguished by their peak serum IL-6 levels, using 400 pg/mL as the cut-off value. Although the difference of flow cytometric data did not reach the level of statistical significance, the levels of pro-inflammatory cytokines and the frequencies of intermediate monocytes (CD14(+)CD16(+)), IFN-gamma(+) CD4(+) or CD8(+) T cells, and HLA-DR+PD-1(+) CD4(+) T cells were higher in the high IL-6 group than in the low IL-6 group. ConclusionThere were distinctive two groups of critical COVID-19 according to serum IL-6 levels having different degrees of cytokinemia and T-cell responses. Our results indicate that the use of immune modulators should be more tailored in patients with critical COVID-19. | - |
dc.language | 영어 | - |
dc.publisher | Frontiers Media S.A. | - |
dc.title | Different degree of cytokinemia and T-cell activation according to serum IL-6 levels in critical COVID-19 | - |
dc.type | Article | - |
dc.identifier.doi | 10.3389/fimmu.2023.1110874 | - |
dc.citation.journaltitle | Frontiers in Immunology | - |
dc.identifier.wosid | 000971246000001 | - |
dc.identifier.scopusid | 2-s2.0-85153448386 | - |
dc.citation.volume | 14 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Shin, Hyun Mu | - |
dc.contributor.affiliatedAuthor | Kim, Hang-Rae | - |
dc.contributor.affiliatedAuthor | Park, Wan Beom | - |
dc.contributor.affiliatedAuthor | Oh, Myoung-don | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordAuthor | immune response | - |
dc.subject.keywordAuthor | cytokine | - |
dc.subject.keywordAuthor | IL-6 | - |
dc.subject.keywordAuthor | T cell | - |
dc.subject.keywordAuthor | critical COVID-19 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.